|
Palo Alto, CA, February 17, 2005 — Telik, Inc. (Nasdaq: TELK) announced that its quarterly conference call will be held on Thursday, February 24, 2005 at 4:30 p.m. Eastern time ( 1:30 p.m. Pacific time). The call will follow the release of Telik’s financial results for the fourth quarter and year ended December 31, 2004 earlier that day.
The conference call will be accessible via Telik’s website at www.telik.com or by telephone at 800-553-5260 or 612-332-0802. An archive of the conference call will be available on the Telik website from approximately 8:00 p.m. Eastern time on February 24 through March 3, 2005 , or by telephone at 800-475-6701 or 320-365-3844, access code 770804.
Telik, Inc. of Palo Alto , CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate which is in Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
